Newsroom

as of 6:00pm ET

Dear Valued Client,

Important Announcement

NeoGenomics Lab Operations | Hurricane Ian

Drug development is rapidly outpacing our ability to bring companion diagnostics to market.

Cancer claims more than half a million lives each year in the United States alone.

With the first TKI therapy Imatinib (Gleevec) targeting the fusion BCR-ABL1, approved by FDA in 2001, we have witnessed the birth of modern targeted therapy and personalized medicine.

NeoGenomics will be exhibiting at the 2022 ASCO Annual Meeting from June 4 – 6, 2022.

Join NeoGenomics for our upcoming Diagnostic Symposium on Tuesday, May 10, 9 to 10 a.m. PT.

On Saturday, March the 12th, after 28 days in China, I was finally allowed to travel to Suzhou.